The possible cost effectiveness of peripheral blood stem cell mobilization with clophosphamide and the late addition of G-CSF
Journal of Korean Medical Science
; : 49-52, 2000.
Article
de En
| WPRIM
| ID: wpr-43385
Bibliothèque responsable:
WPRO
ABSTRACT
The purpose of this study was to develop a cost-effective protocol for the mobilization of peripheral blood stem cells (PBSC) in patients with malignancy. Thirty consecutive patients were randomized to mobilize PBSC with the late addition of a standard 250 microg dose of G-CSF (Neutrogen) from day 8 or early addition of the same dose of G-CSF from day 2, following cyclophosphamide (CY) 4 g/m2. The median yield of CD34+ cells from evaluated patients was 7.87 x 10(6)/kg (range, 2.06-27.25), collected in a median of four apheresis (range, 2-9). Target CD34 + cell doses > or = 2.0 x 10(6)/kg were achieved in all patients able to be evaluated. There were no statistically significant differences in CD34+ cell yields or toxicities. Overall engraftment occurred with median days to neutrophils > or = 0.5 x 10(9)/L or platelets > 20 x 10(9)/L of 11 and 17 days, respectively. However, the duration of G-CSF administration was markedly shorter in the late use of G-CSF group than in the early use of G-CSF group, with a median of 9 days compared with 15 days (p>0.001). PBSC harvesting after priming with CY plus delayed use of G-CSF made it a safe and cost-effective procedure.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Sarcome d'Ewing
/
Lymphome malin non hodgkinien
/
Tumeurs du sein
/
Calendrier d'administration des médicaments
/
Cellules souches hématopoïétiques
/
Étude comparative
/
Facteur de stimulation des colonies de granulocytes
/
Analyse coût-bénéfice
/
Transplantation de cellules souches hématopoïétiques
/
Antinéoplasiques alcoylants
Type d'étude:
Clinical_trials
/
Health_economic_evaluation
Limites du sujet:
Adult
/
Aged
/
Female
/
Humans
/
Male
langue:
En
Texte intégral:
Journal of Korean Medical Science
Année:
2000
Type:
Article